|
Gene: FAM35A |
Gene summary for FAM35A |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM35A | Gene ID | 54537 |
Gene name | shieldin complex subunit 2 | |
Gene Alias | FAM35A | |
Cytomap | 10q23.2 | |
Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q86V20 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54537 | FAM35A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.37e-47 | 7.31e-01 | 0.294 |
54537 | FAM35A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.11e-13 | 1.14e+00 | 0.3487 |
54537 | FAM35A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.42e-20 | 6.47e-01 | 0.281 |
54537 | FAM35A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.21e-39 | 8.23e-01 | 0.3859 |
54537 | FAM35A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.98e-12 | 4.35e-01 | 0.2585 |
54537 | FAM35A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.80e-25 | 4.85e-01 | 0.3005 |
54537 | FAM35A | P1T-E | Human | Esophagus | ESCC | 2.49e-03 | 1.72e-01 | 0.0875 |
54537 | FAM35A | P2T-E | Human | Esophagus | ESCC | 3.00e-12 | 2.09e-01 | 0.1177 |
54537 | FAM35A | P4T-E | Human | Esophagus | ESCC | 7.40e-09 | 1.53e-01 | 0.1323 |
54537 | FAM35A | P5T-E | Human | Esophagus | ESCC | 2.46e-03 | 8.70e-02 | 0.1327 |
54537 | FAM35A | P8T-E | Human | Esophagus | ESCC | 3.14e-19 | 2.81e-01 | 0.0889 |
54537 | FAM35A | P9T-E | Human | Esophagus | ESCC | 4.45e-11 | 1.33e-01 | 0.1131 |
54537 | FAM35A | P10T-E | Human | Esophagus | ESCC | 1.60e-13 | 9.68e-02 | 0.116 |
54537 | FAM35A | P11T-E | Human | Esophagus | ESCC | 8.37e-09 | 1.68e-01 | 0.1426 |
54537 | FAM35A | P12T-E | Human | Esophagus | ESCC | 3.19e-18 | 3.62e-01 | 0.1122 |
54537 | FAM35A | P15T-E | Human | Esophagus | ESCC | 6.58e-11 | 1.67e-01 | 0.1149 |
54537 | FAM35A | P16T-E | Human | Esophagus | ESCC | 2.61e-19 | 2.33e-01 | 0.1153 |
54537 | FAM35A | P17T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.21e-01 | 0.1278 |
54537 | FAM35A | P19T-E | Human | Esophagus | ESCC | 3.13e-08 | 4.50e-01 | 0.1662 |
54537 | FAM35A | P20T-E | Human | Esophagus | ESCC | 4.62e-18 | 2.39e-01 | 0.1124 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM35A | SNV | Missense_Mutation | c.2467N>A | p.Glu823Lys | p.E823K | Q86V20 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM35A | SNV | Missense_Mutation | c.727N>T | p.Leu243Phe | p.L243F | Q86V20 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FAM35A | SNV | Missense_Mutation | novel | c.1666N>A | p.Asp556Asn | p.D556N | Q86V20 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
FAM35A | insertion | Frame_Shift_Ins | novel | c.889_890insAGGT | p.Thr297LysfsTer6 | p.T297Kfs*6 | Q86V20 | protein_coding | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
FAM35A | insertion | Nonsense_Mutation | novel | c.2468_2469insATGAAGAACATTTGCAAGTGCTATTAGG | p.Lys824Ter | p.K824* | Q86V20 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
FAM35A | SNV | Missense_Mutation | novel | c.589N>C | p.Glu197Gln | p.E197Q | Q86V20 | protein_coding | tolerated(0.34) | benign(0.053) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FAM35A | SNV | Missense_Mutation | novel | c.2660N>T | p.Ser887Phe | p.S887F | Q86V20 | protein_coding | tolerated(0.69) | benign(0.332) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
FAM35A | SNV | Missense_Mutation | c.610C>T | p.His204Tyr | p.H204Y | Q86V20 | protein_coding | tolerated(0.05) | benign(0.132) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM35A | SNV | Missense_Mutation | c.791N>A | p.Pro264His | p.P264H | Q86V20 | protein_coding | tolerated(0.4) | benign(0.087) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
FAM35A | SNV | Missense_Mutation | novel | c.1945N>G | p.Gln649Glu | p.Q649E | Q86V20 | protein_coding | tolerated(0.06) | benign(0.122) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |